PharVision Advisers’s Delcath Systems DCTH Stock Holding History

PharVision Advisers’s Portfolio DCTH Stock Details DCTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,220	Closed	-$113K	–	248
2025 Q4	$113K	Sell	11,220 -3,815	-25%	-$37.9K	0.06%	644
2025 Q3	$162K	Buy	+15,035	New	+$168K	0.09%	556
2025 Q1	–	Sell	-10,738	Closed	-$129K	–	328
2024 Q4	$129K	Buy	+10,738	New	+$113K	0.11%	358

Other funds holding DCTH

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PWAC

Private Wealth Advisors (California) Fresno, California $356M AUM 26.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PharVision Advisers's DCTH Position: Q1 2026 in Review

PharVision Advisers sold out of Delcath Systems (DCTH) in Q1 2026, closing a stake of 11,220 shares — an estimated $113K sold.

PharVision Advisers first reported a position in DCTH in Q4 2024 and held it in 3 quarters. The position peaked at $162K in Q3 2025. 121 funds tracked by Wall St. Rank hold DCTH as of Q1 2026.

PharVision Advisers reported no remaining Delcath Systems position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 11,220 Delcath Systems shares in Q1 2026, an estimated $113K.
PharVision Advisers first reported a position in Delcath Systems in Q4 2024 and held it in 3 quarters.
PharVision Advisers's Delcath Systems position peaked at $162K in Q3 2025.
121 funds tracked by Wall St. Rank held Delcath Systems as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.